现在在等人， 先上来看看。
看看大家， 向老朋友们问声好， 希望你们多保重。 每次上来看到熟悉的名字和头像都很开心， 迷糊多谢你们的理解和支持， 特别是当迷糊有时也迷惘时， 你们劝慰我的话真的很贴心。
看到坛子上面现在很乱， 一些乱七八糟的什么人都来了。 医院做广告的， 卖药的， 自称自己是当代李时珍的， 或者治愈大师的。 坛子就像个社会， 我们现在的社会很乱， 大家一定要学习保护好自己 首先自己的健康最重要， 要相信国家的医院， 不能治愈就是不能治愈。 其次要保护好自己的银袋子， 不要象迷糊一样被人把钱骗了。 三就是要保护好自己的私隐， 不要轻易把自己的姓名地址让人知道。
总之， 好人坏人大家难分辨， 但也好分辨。 我们是战友， 但我们不是坏人， 我相信这里的很多受害者都是非常优秀的， 心地善良的， 正直的人。 所以大家要相信， 上帝不会看着我们受苦， 最终他一定会来解救大家。
我也愿这里的战友多多保重， 如果这段时间这里这么乱， 大家还是少些来这里。 等这些乱世魔王走了后， 大家再一起探讨。
估计坛子里面现在根本没有版主， 所以这样下去我也担心这个坛子最终的命运。 但是希望迷糊的楼里可以保持一片净土， 请各种李时珍华佗们还有卖药的远离我的楼， 迷糊真的不喜欢你们！！
先看看最新的一个消息。 一家没有上市的研究所也在研究这个二型疱疹， 今年下半年应该开始人体临床试验吧。 是疫苗， 是预防加上抑制的吧。
主保佑我们
迷糊
Coridon Pty Ltd was founded in 2000 as a private unlisted company, to develop and commercialise patented technology for improving immune responses to polynucleotide vaccines licensed from the University of Queensland by the founder inventor Prof Ian Frazer. The company has laboratories within the research facility at the Princess Alexandra Hospital in Brisbane.
The company’s overall objective is to utilise its unique optimisation technology to produce prophylactic and/or therapeutic polynucleotide vaccines for a range of infectious diseases and cancers in humans. Product development is currently focused on herpesvirus vaccines.
http://www.coridon.com/Current Development Program
Herpes Simplex Virus Type 2 (HSV-2)
HSV-2 is the major causative agent of genital herpes. This disease does not just cause discomfort to infected individuals but can have serious health implications for babies born to infected women and is believed to aid the transmission of human immunodeficiency virus (HIV). Current HSV treatment involves the use of antiviral drugs which can reduce, but not eliminate, outbreaks and shedding and therefore does not prevent spread of the disease. Coridon is currently in the pre-clinical phase of evaluating a combined prophylactic and therapeutic HSV-2 vaccine with a view to commencing a human phase 1b clinical trial in late 2011.
Epstein Barr Virus (EBV)
EBV is the causative agent of infectious mononucleosis (IM; glandular fever) in young adults and has been linked with Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s disease, non-Hodgkin’s lymphoma and lymphoproliferative diseases in the immunosupressed. Coridon is about to commence development of a prophylactic/therapeutic vaccine for EBV: prophylactic for IM and post-transplant lymphoproliferative disease and therapeutic for recurrent infection as a cause of NPC (in Asia) and lymphoma (in Africa).
Coridon’s optimisation technology could potentially be applied to the development of DNA vaccines for a range of infectious diseases and cancers. Furthermore, as the technology should stimulate not only a strong antibody response but also a robust cellular immune response, it is particularly suited to the development of therapeutic vaccines. Another potential target that Coridon may pursue in 2011 is a therapeutic vaccine for cervical cancer.
Coridon Pty Ltd was founded in 2000 as a private unlisted company, to develop and commercialise patented technology for improving immune responses to polynucleotide vaccines licensed from the University of Queensland by the founder inventor Prof Ian Frazer. The company has laboratories within the research facility at the Princess Alexandra Hospital in Brisbane.
The company’s overall objective is to utilise its unique optimisation technology to produce prophylactic and/or therapeutic polynucleotide vaccines for a range of infectious diseases and cancers in humans. Product development is currently focused on herpesvirus vaccines.
http://www.coridon.com/Current Development Program
Herpes Simplex Virus Type 2 (HSV-2)
HSV-2 is the major causative agent of genital herpes. This disease does not just cause discomfort to infected individuals but can have serious health implications for babies born to infected women and is believed to aid the transmission of human immunodeficiency virus (HIV). Current HSV treatment involves the use of antiviral drugs which can reduce, but not eliminate, outbreaks and shedding and therefore does not prevent spread of the disease. Coridon is currently in the pre-clinical phase of evaluating a combined prophylactic and therapeutic HSV-2 vaccine with a view to commencing a human phase 1b clinical trial in late 2011.
Epstein Barr Virus (EBV)
EBV is the causative agent of infectious mononucleosis (IM; glandular fever) in young adults and has been linked with Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s disease, non-Hodgkin’s lymphoma and lymphoproliferative diseases in the immunosupressed. Coridon is about to commence development of a prophylactic/therapeutic vaccine for EBV: prophylactic for IM and post-transplant lymphoproliferative disease and therapeutic for recurrent infection as a cause of NPC (in Asia) and lymphoma (in Africa).
Coridon’s optimisation technology could potentially be applied to the development of DNA vaccines for a range of infectious diseases and cancers. Furthermore, as the technology should stimulate not only a strong antibody response but also a robust cellular immune response, it is particularly suited to the development of therapeutic vaccines. Another potential target that Coridon may pursue in 2011 is a therapeutic vaccine for cervical cancer.
